ESMO data show G1 Therapeutics could make a difference in breast cancer

28 September 2019

North Carolina, USA-based G1 Therapeutics (Nasdaq: GTHX) has reported overall survival (OS) data at the European Society of Medical Oncology (ESMO), which suggest trilaciclib could have a significant impact in breast cancer.

The data, reported as part of a late-breaking oral presentation at the 2019 ESMO congress, were also published in The Lancet, with more data from a separate Phase II trial in small cell lung cancer (SCLC) due on Sunday.

Based on the data, the firm will begin a rolling New Drug Application (NDA) submission for SCLC, in the fourth quarter of this year. The firm has also been talking to the US regulator about the design of a Phase III trial in breast cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK